4D Molecular Therapeutics, Inc. Cash Flow Statement

Cash Flow Statement Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Operating Activities
Net Income -49.26M-56.51M-71.20M-107.46M-100.66M-160.79M
Depreciation and Depletion 1.00M1.40M1.50M2.40M4.40M4.80M
Share-based Compensation 3.54M4.98M13.80M17.12M19.66M26.12M
Gains from Sales and Divestitures 0.05M
Gains from Investment Securities 2.47M3.19M3.88M5.78M8.24M9.34M
Non-cash Items 19.97M97.11M1.59M2.38M46.86M54.50M
Cash from Operations -36.71M-50.91M-69.13M-86.69M-75.79M-134.59M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles 1.50M1.48M1.54M7.18M
Depreciation & Amortization (CF) 1.00M1.44M1.52M2.40M4.20M4.65M
Change in Working Capital
Change in Receivables -0.15M0.51M-1.44M-0.05M
Change in Account Payables 0.53M0.04M2.29M-1.64M0.90M0.87M
Change in Accured Expenses 3.84M1.90M0.69M2.48M3.37M6.52M
Investing Activities
Capital Expenditures 3.20M1.00M9.11M11.54M2.77M3.79M
Change in Acquisitions & Divestments 5.00M147.80M173.29M169.00M
Cash from Investing Activities -3.20M-1.00M-172.68M-17.05M115.72M-302.44M
Financing Activities
Other financing activities 0.47M
Change in Capital Stock
Shares Issued -2.26M205.66M114.30M129.21M15.30M
Preferred Shares Issued -0.01M72.47M
Misc.
Cash from Financing Activities -2.19M278.98M118.09M3.08M156.83M337.25M
Change in Cash -42.11M227.07M-123.72M-100.65M196.76M-99.77M
Free Cash Flow -39.91M-51.91M-78.24M-98.22M-78.56M-138.37M
Net Cash Flow -42.11M227.07M-123.72M-100.65M196.76M-99.77M